"10.1371_journal.pone.0070701","plos one","2013-08-14T00:00:00Z","Thomas A Munro; Xi-Ping Huang; Carmela Inglese; Maria Grazia Perrone; Ashlee Van't Veer; F Ivy Carroll; Cécile Béguin; William A Carlezon; Nicola A Colabufo; Bruce M Cohen; Bryan L Roth","McLean Hospital, Belmont, Massachusetts, United States of America; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, United States of America; School of Chemistry and Bio21 Institute, University of Melbourne, Parkville, Australia; National Institute of Mental Health Psychoactive Drug Screening Program and Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America; Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari, Bari, Italy; Center for Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, North Carolina, United States of America","Conceived and designed the experiments: CB FIC WAC BMC NAC XPH CI MGP BLR AVV. Performed the experiments: XPH CI MGP NAC. Analyzed the data: XPH CI MGP NAC BLR. Contributed reagents/materials/analysis tools: FIC. Wrote the paper: TAM.","The authors have read the journals policy and have the following conflicts: CB, BMC, and WAC hold US patents on the use of κ ligands to treat mood disorders (6,528,518 and 7,629,475). RTI holds several US patents on the preparation and therapeutic use of JDTic, on which FIC is an author. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","08","Thomas A Munro","TAM",11,TRUE,10,4,5,1,TRUE,FALSE,FALSE,0,NA,FALSE
